Lexicon Pharmaceuticals Inc
LXRX1.135USD
+0.065+6.07%
交易中 （美东）报价延迟15分钟
412.21M总市值
亏损市盈率 TTM
关于 Lexicon Pharmaceuticals Inc 公司
Lexicon Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于发现、开发和商业化用于治疗人类疾病的药品。该公司的产品线包括 INPEFA（索他格列净）、LX9211 和 LX9851。索他格列净是一种口服小分子化合物，正在开发用于治疗心力衰竭和 I 型糖尿病以及 II 型糖尿病、慢性肾病和其他心血管风险因素。LX9211 是一种口服小分子化合物，正在开发用于治疗神经性疼痛。该公司正在对 LX9211 进行糖尿病周围神经性疼痛的 II 期临床试验和对 LX9211 进行带状疱疹后神经痛的 II 期临床试验。该公司正在对口服小分子候选药物 LX9851 进行临床前开发，作为肥胖症的治疗方法和体重管理的工具。
公司简介
公司代码LXRX
公司名称Lexicon Pharmaceuticals Inc
上市日期Apr 07, 2000
CEOMr. Michael Exton
员工数量103
证券类型Ordinary Share
年结日Apr 07
公司地址2445 Technology Forest Blvd
城市THE WOODLANDS
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编77381
电话12818633000
网址https://www.lexpharma.com/
公司代码LXRX
上市日期Apr 07, 2000
CEOMr. Michael Exton
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Dr. Judith L. Swain, M.D.
Dr. Judith L. Swain, M.D.
Independent Director
Independent Director
85.17K
+76.11%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Independent Director
Independent Director
36.81K
--
Ms. Wendy E. Mcdermott
Ms. Wendy E. Mcdermott
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
Ms. Kristen L. Alexander
Ms. Kristen L. Alexander
Vice President - Finance and Accounting
Vice President - Finance and Accounting
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
持股股东
持股股东
占比
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
股东类型
持股股东
占比
Investment Advisor
68.24%
Hedge Fund
3.93%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
1.23%
Research Firm
0.50%
Family Office
0.06%
Bank and Trust
0.05%
Pension Fund
0.01%
Other
22.25%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
320
282.21M
77.71%
-40.09M
2025Q1
325
276.43M
76.32%
-62.57M
2024Q4
309
308.33M
85.37%
-6.09M
2024Q3
300
300.67M
83.18%
-4.62M
2024Q2
291
290.96M
80.51%
+37.02M
2024Q1
279
184.47M
74.41%
-20.75M
2023Q4
274
194.11M
79.36%
-11.88M
2023Q3
271
200.84M
82.07%
-4.66M
2023Q2
276
200.76M
82.17%
+43.01M
2023Q1
274
154.64M
82.03%
-4.81M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Artal International S.C.A.
136.18M
37.5%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
38.92M
10.72%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
34.54M
9.51%
-17.43M
-33.53%
Mar 31, 2025
The Vanguard Group, Inc.
9.56M
2.63%
-278.32K
-2.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.21M
2.54%
-237.79K
-2.52%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
8.21M
2.26%
+654.37K
+8.66%
Mar 31, 2025
Ulys, L.L.C.
5.45M
1.5%
--
--
Dec 05, 2024
Geode Capital Management, L.L.C.
3.69M
1.02%
+168.02K
+4.77%
Mar 31, 2025
GSA Capital Partners LLP
807.49K
0.22%
+807.49K
--
Mar 31, 2025
State Street Global Advisors (US)
2.61M
0.72%
-110.67K
-4.07%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0%
Texas Capital Texas Equity Index ETF
0%
Goldman Sachs Innovate Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Growth ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.68%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0%
Texas Capital Texas Equity Index ETF
占比0%
Goldman Sachs Innovate Equity ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
